American Pain Foundation

The American Pain Foundation was a nonprofit included in a 2012 Senate investigation examining ties between pain advocacy organizations and pharmaceutical companies. Its appearance in the inquiry placed it within the national debate over opioid promotion and chronic-pain treatment, but the investigation’s results were sealed, so the account does not establish what the Foundation itself did or what conclusions investigators reached about it.

Organizational Place and Context

The Foundation is identified as one of several nonprofit organizations scrutinized amid growing concern about the relationship between pain advocacy and drug-industry interests. That scrutiny arose during a period when medical practice was changing: in 1996, the introduction of OxyContin coincided with the adoption of pain as the fifth vital sign, and in 1999 the Joint Commission on Accreditation of Healthcare Organizations approved mandatory pain-assessment and treatment standards.

Those developments formed part of the broader setting, not a documented account of the Foundation’s own conduct. The book describes the American Pain Society and the American Academy of Pain Medicine as organizations that promoted expanded opioid use for long-term chronic pain while receiving millions from companies that manufactured the drugs. It does not attribute those same actions or funding arrangements specifically to the American Pain Foundation.

Scrutiny of Advocacy and Industry Ties

Journalist John Fauber reported on the relationship between pain organizations and pharmaceutical companies, including industry money received by the American Pain Society and the American Academy of Pain Medicine as they supported expanded opioid use for chronic pain. His reporting widened attention from prescribing practices and drug marketing to the organizations helping shape the public and professional understanding of pain treatment.

The resulting concern was institutional: advocacy groups could influence the direction of pain policy while pharmaceutical companies stood to benefit from broader opioid use. The American Pain Foundation was included among the organizations brought into that scrutiny, but the available account does not detail its funding, policy positions, or role in promoting particular drugs. Its inclusion should therefore not be treated as proof that it shared the documented conduct attributed to the other pain organizations.

The 2012 Senate Investigation

Fauber’s articles prompted a 2012 Senate investigation led by Senators Chuck Grassley and Max Baucus. The inquiry targeted the American Pain Foundation and Purdue Pharma, as well as other nonprofit organizations and pharmaceutical companies, focusing on relationships between the pain-advocacy world and the drug industry.

The investigation gave the Foundation a place in a formal congressional examination of those relationships. However, the account supplies no specific allegation against the Foundation and identifies no finding particular to it. It establishes that the organization was targeted by the inquiry, not that investigators publicly determined it had acted improperly.

Sealed Findings and Unresolved Record

The Senate Finance Committee’s results were sealed and remained undisclosed despite periodic calls for their release. Dr. Steve Gelfand, an addiction specialist and activist who had helped Barbara Van Rooyan file an FDA recall petition, said that many people had welcomed the investigation but that it was never followed up on. He characterized the lack of follow-through as a political power play.

With the report unavailable, the inquiry’s public legacy is defined by both its scope and its silence. The American Pain Foundation was among the organizations examined, but the sealed record prevents the account from specifying what evidence concerned it, whether investigators reached conclusions about it, or how the inquiry affected its work.